Hyderabad: Nearly 30% of individuals lost their vaccine-acquired Immunity After six months, a study was done to understand the longevity of Vaccination Immunity has been found in relation to the level of immunity in the Indian population.
The study was conducted by AIG Hospitals with the Asian Healthcare Foundation on 1,636 health care workers The country has been fully vaccinated with three of the COVID-19 vaccines currently being administered. Of the 1,636 participants included in the study, 93% (1519 individuals) had received CowishieldFound 6.2% (102) covaxin and less than 1% (13) was administered Artificial satellite jab
The study results were uploaded on Wednesday to Pre-Print Server Research, a preprint platform where research papers are uploaded before they are peer-reviewed.
Researchers involved in the study measured IgG Anti-S1 and IgG anti-S2 antibodies to SARS-CoV-2 in these 1,636 individuals. People who had antibody levels less than 15 AU/mL were considered antibody negative, meaning they had not developed any protective immunity against the virus.
Furthermore, it was estimated that an antibody level of 100 AU/ml is the minimum level for protection against the virus, meaning that anyone with an antibody level less than 100 AU/ml is susceptible to be infected.
“The results of our study were on par with other global studies where we found that approximately 30% of individuals had antibody levels below the protective immunoreactivity level of 100 AU/mL after six months. These were those with co-morbidities such as hypertension and diabetes. The individuals were majorly above 40 years of age. Out of the total, 6% did not develop any immune defenses,” said Dr D Nageswar reddy, President, AIG Hospitals, who is one of the researchers.
The researchers point out that these results clearly indicate that with age, the decrease in immunity is directly proportional which means that younger people tend to have more sustained antibody levels than the elderly population.
Individuals of both sexes over 40 years of age and over 40 years of age with co-morbidities such as hypertension and diabetes showing a significantly lower antibody response six months after complete vaccination, and those with co-morbidities such as hypertension and diabetes. May be at high risk of suffering from morbidity. infection and therefore preference should be given to a booster dose after six months.
“Currently, a nine-month gap for prevention doses benefits 70% of the population who can maintain adequate antibody levels for more than six months. However, considering the scale of our country, 30% of the people especially those with co-morbid conditions like hypertension, diabetes, who are more prone to develop the infection six months after full vaccination, should also be prevented Dosage should be considered. Dr Reddy added.
Pointing out that the country is currently seeing an increase in infections, he said: “Fortunately, the severity of the disease is mild due to a number of factors, including the effects of vaccination, the intrinsic character of the type itself, and the natural immunity among the population. . . however. , we need to devise strategies that ensure minimal spread and protect as many people as possible. The study aims to understand the effectiveness of current vaccines in the long term and to see if there are specific population demographics that need to be treated as soon as possible. Booster is required,” Reddy said.
The study was conducted by AIG Hospitals with the Asian Healthcare Foundation on 1,636 health care workers The country has been fully vaccinated with three of the COVID-19 vaccines currently being administered. Of the 1,636 participants included in the study, 93% (1519 individuals) had received CowishieldFound 6.2% (102) covaxin and less than 1% (13) was administered Artificial satellite jab
The study results were uploaded on Wednesday to Pre-Print Server Research, a preprint platform where research papers are uploaded before they are peer-reviewed.
Researchers involved in the study measured IgG Anti-S1 and IgG anti-S2 antibodies to SARS-CoV-2 in these 1,636 individuals. People who had antibody levels less than 15 AU/mL were considered antibody negative, meaning they had not developed any protective immunity against the virus.
Furthermore, it was estimated that an antibody level of 100 AU/ml is the minimum level for protection against the virus, meaning that anyone with an antibody level less than 100 AU/ml is susceptible to be infected.
“The results of our study were on par with other global studies where we found that approximately 30% of individuals had antibody levels below the protective immunoreactivity level of 100 AU/mL after six months. These were those with co-morbidities such as hypertension and diabetes. The individuals were majorly above 40 years of age. Out of the total, 6% did not develop any immune defenses,” said Dr D Nageswar reddy, President, AIG Hospitals, who is one of the researchers.
The researchers point out that these results clearly indicate that with age, the decrease in immunity is directly proportional which means that younger people tend to have more sustained antibody levels than the elderly population.
Individuals of both sexes over 40 years of age and over 40 years of age with co-morbidities such as hypertension and diabetes showing a significantly lower antibody response six months after complete vaccination, and those with co-morbidities such as hypertension and diabetes. May be at high risk of suffering from morbidity. infection and therefore preference should be given to a booster dose after six months.
“Currently, a nine-month gap for prevention doses benefits 70% of the population who can maintain adequate antibody levels for more than six months. However, considering the scale of our country, 30% of the people especially those with co-morbid conditions like hypertension, diabetes, who are more prone to develop the infection six months after full vaccination, should also be prevented Dosage should be considered. Dr Reddy added.
Pointing out that the country is currently seeing an increase in infections, he said: “Fortunately, the severity of the disease is mild due to a number of factors, including the effects of vaccination, the intrinsic character of the type itself, and the natural immunity among the population. . . however. , we need to devise strategies that ensure minimal spread and protect as many people as possible. The study aims to understand the effectiveness of current vaccines in the long term and to see if there are specific population demographics that need to be treated as soon as possible. Booster is required,” Reddy said.
,